Unexpected, isolated activated partial thromboplastin time prolongation: A practical mini-review.
Algorithms
Blood Coagulation
Blood Coagulation Disorders
/ diagnosis
Blood Coagulation Factors
Clinical Decision-Making
Diagnosis, Differential
Disease Management
Disease Susceptibility
Drug Interactions
Humans
Incidental Findings
International Normalized Ratio
Lupus Coagulation Inhibitor
Partial Thromboplastin Time
/ methods
Prevalence
activated partial thromboplastin time
hemophilia
lupus anticoagulants
Journal
European journal of haematology
ISSN: 1600-0609
Titre abrégé: Eur J Haematol
Pays: England
ID NLM: 8703985
Informations de publication
Date de publication:
Jun 2020
Jun 2020
Historique:
received:
27
12
2019
revised:
07
02
2020
accepted:
07
02
2020
pubmed:
13
2
2020
medline:
9
2
2021
entrez:
13
2
2020
Statut:
ppublish
Résumé
A common inquiry in coagulation laboratories is how to interpret an unexpected, isolated prolonged activated partial thromboplastin time (APTT). In this context, isolated means together with a normal prothrombin time (PT) and/or normal international normalized ratio (INR). This finding may lead to contact with laboratory doctors for further advice on a diagnostic strategy. Occasionally, the need for a diagnostic algorithm can be subacute, where surgery has to be postponed until an explanation for the isolated, prolonged APTT has been established. Activated partial thromboplastin time as a coagulation test was developed to monitor patients with hemophilia. Different APTT reagents display considerable differences in their sensitivity to deficiencies of coagulation factors. An isolated, prolonged APTT is seen in (a) individuals/patients with lupus anticoagulants, (b) patients in treatment with anticoagulants, mainly heparin, and (c) patients with deficiencies of specific coagulation factors. In this tutorial review, we summarize what may cause an isolated prolonged APTT and we present a simple diagnostic algorithm to differentiate between lupus anticoagulants (common) and factor deficiencies (rare). The identification of an isolated prolonged APTT as well as the underlying cause can be of the utmost importance in ensuring the correct therapeutic follow-up.
Substances chimiques
Blood Coagulation Factors
0
Lupus Coagulation Inhibitor
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
519-525Informations de copyright
© 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Références
White GC. The partial thromboplastin time: defining an era in coagulation. J Thromb Haemost. 2003;1:2267-2270.
Dam H, Venndt H. Observations on the coagulation of blood plasma in haemophilia. Lancet. 1940;238:70-72.
Higgins RA, Kitchen S, Chen D. Hemostasis. In: Rifai N, Horvath AR, Wittwer CT, eds. Tietz Textbook of Clinical Chemistry and Molecular Diagnostics, 6th edn. Boston, MA: Elsevier; 2017:1732.e1-1732.e56.
Proctor RR, Rapaport SI. The partial thromboplastin time with kaolin. A simple screening test for first stage plasma clotting factor deficiencies. Am J Clin Pathol. 1961;36:212-219.
Bowyer A, Kitchen S, Makris M. The responsiveness of different APTT reagents to mild factor VIII, IX and XI deficiencies. Int J Lab Hematol. 2011;33:154-158.
White GC, Rosendaal F, Aledort LM, Lusher JM, Rothschild C, Ingerslev J. Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost. 2001;85:560.
Mannucci PM, Tuddenham EG. The hemophilias-from royal genes to gene therapy. N Engl J Med. 2001;344:1773-1779.
Favaloro EJ, Kershaw G, Mohammed S, Lippi G. How to optimize activated partial thromboplastin time (APTT) testing: solutions to establishing and verifying normal reference intervals and assessing APTT reagents for sensitivity to heparin, lupus anticoagulant, and clotting factors. Semin Thromb Hemost. 2019;45:22-35.
Kitchen S, Makris M. Laboratory tests of hemostasis. In: Key N, Makris M, O'Shaughnessy D, Lillecrap D, eds. Practical Hemostasis and Thrombosis, 2nd edn. London, UK: Blackwell Publishing Ltd.; 2009:7-16.
Tripodi A, Mannucci PM. The coagulopathy of chronic liver disease. N Engl J Med. 2011;365:147-156.
Gaarder C, Naess PA, Christensen EF, et al. Scandinavian Guidelines-"The massively bleeding patient". Scand J Surg. 2008;97:15-36.
Wada H, Thachil J, Nisio MD, et al. Guidance for diagnosis and treatment of DIC from harmonization of the recommendations from three guidelines. J Thromb Haemost. 2013. https://doi.org/10.1111/jth.12155. [Epub ahead of print].
Wada H, Matsumoto T, Yamashita Y. Diagnosis and treatment of disseminated intravascular coagulation (DIC) according to four DIC guidelines. J Intensive Care. 2014;2:15.
de Moerloose P, Casini A, Neerman-Arbez M. Congenital fibrinogen disorders: an update. Semin Thromb Hemost. 2013;39:585-595.
Tripodi A. Laboratory testing for lupus anticoagulants: a review of issues affecting results. Clin Chem. 2007;53:1629-1635.
Bajaj SP, Rapaport SI, Fierer DS, Herbst KD, Schwartz DB. A mechanism for the hypoprothrombinemia of the acquired hypoprothrombinemia-lupus anticoagulant syndrome. Blood. 1983;61:684-692.
Baca V, Montiel G, Meillon L, et al. Diagnosis of lupus anticoagulant in the lupus anticoagulant-hypoprothrombinemia syndrome: report of two cases and review of the literature. Am J Hematol. 2002;71:200-207.
Mazodier K, Arnaud L, Mathian A, et al. Lupus anticoagulant-hypoprothrombinemia syndrome: report of 8 cases and review of the literature. Medicine (Baltimore). 2012;91:251-260.
Garcia D, Erkan D. Diagnosis and management of the antiphospholipid syndrome. N Engl J Med. 2018;378:2010-2021.
Devreese KM, Pierangeli SS, de Laat B, et al. Testing for antiphospholipid antibodies with solid phase assays: guidance from the SSC of the ISTH. J Thromb Haemost. 2014;12:792-795.
Pengo V, Ruffatti A, Legnani C, et al. Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. J Thromb Haemost. 2010;8:237-242.
Ruiz-Irastorza G, Cuadrado MJ, Ruiz-Arruza I, et al. Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task force at the 13th International Congress on antiphospholipid antibodies. Lupus. 2011;20:206-218.
Martinelli I, Abbattista M, Bucciarelli P, et al. Recurrent thrombosis in patients with antiphospholipid antibodies treated with vitamin K antagonists or rivaroxaban. Haematologica. 2018;103:e315-e317.
Brancaccio V, Ames PR, Glynn J, Iannaccone L, Mackie IJ. A rapid screen for lupus anticoagulant with good discrimination from oral anticoagulants, congenital factor deficiency and heparin, is provided by comparing a sensitive and an insensitive APTT reagent. Blood Coagul Fibrinolysis. 1997;8:155-160.
Kelsey PR, Stevenson KJ, Poller L. The diagnosis of lupus anticoagulants by the activated partial thromboplastin time-the central role of phosphatidyl serine. Thromb Haemost. 1984;52:172-175.
Tripodi A, Chantarangkul V, Novembrino C, Peyvandi F. Advances in the treatment of hemophilia: implications for laboratory testing. Clin Chem. 2019;65:254-262.
Rocca B, Fox KAA, Ajjan RA, et al. Antithrombotic therapy and body mass: an expert position paper of the ESC Working Group on Thrombosis. Eur Heart J. 2018;39:1672f-1686f.
Watson H, Davidson S, Keeling D. Guidelines on the diagnosis and management of heparin-induced thrombocytopenia: second edition. Br J Haematol. 2012;159:528-540.
Cuker A, Siegal DM, Crowther MA, Garcia DA. Laboratory measurement of the anticoagulant activity of the non-vitamin K oral anticoagulants. J Am Coll Cardiol. 2014;64:1128-1139.
Hauser VM, Rozek SL. Effect of warfarin on the activated partial thromboplastin time. Drug Intell Clin Pharm. 1986;20:964-967.
Kearon C, Johnston M, Moffat K, McGinnis J, Ginsberg JS. Effect of warfarin on activated partial thromboplastin time in patients receiving heparin. Arch Intern Med. 1998;158:1140-1143.
Delgado J, Jimenez-Yuste V, Hernandez-Navarro F, Villar A. Acquired haemophilia: review and meta-analysis focused on therapy and prognostic factors. Br J Haematol. 2003;121:21-35.
Werner EJ, Broxson EH, Tucker EL, Giroux DS, Shults J, Abshire TC. Prevalence of von Willebrand disease in children: a multiethnic study. J Pediatr. 1993;123:893-898.
Rodeghiero F, Castaman G, Dini E. Epidemiological investigation of the prevalence of von Willebrand's disease. Blood. 1987;69:454-459.
Bowman M, Hopman WM, Rapson D, Lillicrap D, Silva M, James P. A prospective evaluation of the prevalence of symptomatic von Willebrand disease (VWD) in a pediatric primary care population. Pediatr Blood Cancer. 2010;55:171-173.
Ruggeri ZM. Structure of von Willebrand factor and its function in platelet adhesion and thrombus formation. Best Pract Res Clin Haematol. 2001;14:257-279.
Lenting PJ, van Mourik JA, Mertens K. The life cycle of coagulation factor VIII in view of its structure and function. Blood. 1998;92:3983-3996.
Sadler JE, Budde U, Eikenboom JC, et al. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. J Thromb Haemost. 2006;4:2103-2114.
Lassila R, Holme PA, Landorph A, Petrini P, Onundarson PT, Hillarp A. Nordic Haemophilia Council's practical guidelines on diagnosis and management of von Willebrand disease. Semin Thromb Hemost. 2011;37:495-502.
Ames PR, Graf M, Archer J, Scarpato N, Iannaccone L. Prolonged activated partial thromboplastin time: difficulties in discriminating coexistent factor viii inhibitor and lupus anticoagulant. Clin Appl Thromb Hemost. 2015;21:149-154.
Cunningham MT, Brandt JT, Laposata M, Olson JD. Laboratory diagnosis of dysfibrinogenemia. Arch Pathol Lab Med. 2002;126:499-505.
Benzon HT, Park M, McCarthy RJ, Kendall MC, Lindholm PF. Mixing studies in patients with prolonged activated partial thromboplastin time or prothrombin time. Anesth Analg. 2019;128:1089-1096.
Chen CL, Lin GA, Bardach NS, et al. Preoperative medical testing in Medicare patients undergoing cataract surgery. N Engl J Med. 2015;372:1530-1538.
Yonekura H, Seto K, Ide K, et al. Preoperative blood tests conducted before low-risk surgery in Japan: a retrospective observational study using a Nationwide Insurance Claims Database. Anesth Analg. 2018;126:1633-1640.
Nieto RM, De Leon LE, Diaz DT, Krauklis KA, Fraser CD Jr. Routine preoperative laboratory testing in elective pediatric cardiothoracic surgery is largely unnecessary. J Thorac Cardiovasc Surg. 2017;153:678-685.
Vries MJ, van der Meijden PE, Kuiper GJ, et al. Preoperative screening for bleeding disorders: a comprehensive laboratory assessment of clinical practice. Res Pract Thromb Haemost. 2018;2:767-777.
Bitar M, Dunya G, Khalifee E, Muwakkit S, Barazi R. Risk of post-operative hemorrhage after adenoidectomy and tonsillectomy: value of the preoperative determination of partial thromboplastin time and prothrombin time. Int J Pediatr Otorhinolaryngol. 2019;116:62-64.
Horlocker TT, Vandermeuelen E, Kopp SL, Gogarten W, Leffert LR, Benzon HT. Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines (Fourth Edition). Reg Anesth Pain Med. 2018;43:263-309.
OʼConnor CR, Reginato AJ, Ing JH, Keech JA. Prolonged activated partial thromboplastin time in systemic lupus erythematosus overlap syndrome: fatal bleeding due to factor VIII inhibitor. J Clin Rheumatol. 1995;1:57-59.
Salem RO, Van Cott EM. A new automated screening assay for the diagnosis of von Willebrand disease. Am J Clin Pathol. 2007;127:730-735.